Name | (5s,12r)-5,12,20-trihydroxy-(6z,8e,10e,14z)-eicosatetraenoic acid |
---|---|
Synonyms |
20-hydroxy-leukotriene B4
20-Hydroxy-LTB4 20-hydroxyleukotriene hydroxyleukotriene B4 (5S,6Z,8E,10E,12R,14Z)-5,12,20-Trihydroxy-6,8,10,14-icosatetraenoic acid LTB4_20-hydroxy 20-OH-LTB4 5S,12R,20-TRIHYDROXY-6Z,8E,10E,14Z-EICOSATETRAENOIC ACID 6,8,10,14-Eicosatetraenoic acid, 5,12,20-trihydroxy-, (5S,6Z,8E,10E,12R,14Z)- MFCD00065858 |
Description | 20-Hydroxy-leukotriene B4 is an endogenous metabolite present in Urine that can be used for the research of Sjogren Larsson Syndrome[1][2]. |
---|---|
Related Catalog | |
Target |
Human Endogenous Metabolite |
In Vitro | Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1]. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 581.8±50.0 °C at 760 mmHg |
Molecular Formula | C20H32O5 |
Molecular Weight | 352.465 |
Flash Point | 319.7±26.6 °C |
Exact Mass | 352.224976 |
PSA | 97.99000 |
LogP | 2.05 |
Vapour Pressure | 0.0±3.7 mmHg at 25°C |
Index of Refraction | 1.542 |
Hazard Codes | F: Flammable;Xi: Irritant; |
---|---|
Risk Phrases | 11-36/37/38 |
Safety Phrases | 16-26-36 |
RIDADR | UN 1170 3/PG 2 |
Precursor 8 | |
---|---|
DownStream 0 |